|
US7033610B2
|
|
Growth-promoting agent
|
|
AUPQ878600A0
|
|
Compositions and methods for the treatment of intact skin
|
|
AUPQ585500A0
|
|
Treatment for peripheral sensory neuropathy
|
|
AUPQ496900A0
|
|
Growth factor splice variant
|
|
AUPP748498A0
|
|
Igf-II binding protein
|
|
AUPP672298A0
|
|
Igf-ii binding protein
|
|
AUPP298498A0
|
|
Matrix binding factor
|
|
AUPP031897A0
|
|
Mammalian milk growth factor
|
|
CA2219895A1
|
|
Selection of livestock using igf levels
|
|
AU5489996A
|
|
Method of preventing or treating alimentary tract damage due to chemotherapy or radiation
|
|
AU2917495A
|
|
Use of insulin-like growth factor in combination with insulin
|
|
AUPN271295A0
|
|
Method of treatment
|
|
AU2298395A
|
|
Modified milk growth factor
|
|
US5679771A
|
|
Method for treating intestinal diseases
|
|
AUPM678294A0
|
|
Use of insulin-like growth factor in combination with insulin
|
|
AUPM534794A0
|
|
Modified milk growth factor
|
|
US5470828A
|
|
Peptide analogs of insulin-like growth factor II
|
|
US5444045A
|
|
Method of administering IGF-1, IGF-2, and analogs thereof to birds
|
|
AU7226291A
|
|
Method for treating intestinal diseases
|
|
CA2074166A1
|
|
Method for treating intestinal diseases
|
